HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (5- (tert- butyl)- 3- (2- fluoro- 5- methylpyridin- 4- yl)- 2- methyl- 1H- indol- 7- yl)methanesulfonamide

structure in first source

Also Known As:

LLY-2707

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - N-(5-(tert-butyl)-3-(2-fluoro-5-methylpyridin-4-yl)-2-methyl-1H-indol-7-yl)methanesulfonamide: 1
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - N-(5-(tert-butyl)-3-(2-fluoro-5-methylpyridin-4-yl)-2-methyl-1H-indol-7-yl)methanesulfonamide: 1
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - N-(5-(tert-butyl)-3-(2-fluoro-5-methylpyridin-4-yl)-2-methyl-1H-indol-7-yl)methanesulfonamide: 1

Experts

1.	Alexander-Chacko, Jesline: 1 article (01/2014)
2.	Barr, Robert J: 1 article (01/2014)
3.	Carson, Mathew W: 1 article (01/2014)
4.	Coghlan, Michael: 1 article (01/2014)
5.	Gehlert, Donald R: 1 article (01/2014)
6.	Morin, Michelle: 1 article (01/2014)
7.	Need, Anne: 1 article (01/2014)
8.	Shaw, Janice: 1 article (01/2014)
9.	Sindelar, Dana K: 1 article (01/2014)

Related Diseases

1.	Weight Gain 01/01/2014 - "To understand the pharmacology responsible for this finding, we discovered LLY-2707 [N-(5-(tert-butyl)-3-(2-fluoro-5-methylpyridin-4-yl)-2-methyl-1H-indol-7-yl)methanesulfonamide], a novel and selective GRA, and evaluated its utility in preclinical models of AAPD-associated weight gain and diabetes. " 01/01/2014 - "At doses effectively preventing weight gain, LLY-2707 did not substantially interfere with the dopamine D2 receptor occupancy by olanzapine. " 01/01/2014 - "LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats."
2.	Body Weight (Weight, Body) 01/01/2014 - "The increases in the body weight of female rats treated with olanzapine (2 mg/kg PO) over 14 days were reduced in a dose-dependent manner by coadministration of LLY-2707. "

Related Drugs and Biologics

1.	Dopamine D2 Receptors (Dopamine D2 Receptor)
2.	Antipsychotic Agents (Antipsychotics)
3.	Glucocorticoids
4.	Olanzapine (Zyprexa)
5.	methanesulfonamide